Mannkind
$6.01
118
+$0.23+3.98% Today
Statistics
Day High
6.03
Day Low
5.63
52W High
6.51
52W Low
3.38
Volume
3,579,171
Avg. Volume
3,741,954
Mkt Cap
1.85B
P/E Ratio
50.82
Dividend Yield
-
Dividend
-
Upcoming
Earnings
3MarExpected
Expected EPS
0.016667
Actual EPS
N/A
Financials
9.66%Profit Margin
Profitable571.01MRevenue
55.18MNet Income
Analyst Ratings
$10.10Average Price Target
The highest estimate is 15.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MNKD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Sanofi
SNY
Mkt Cap124.45B
Novo Nordisk
NVO
Mkt Cap217.54B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Astrazeneca
AZN
Mkt Cap256.58B
Merck
MRK
Mkt Cap214.76B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Tandem Diabetes Care
TNDM
Mkt Cap945.97M
Insulet
PODD
Mkt Cap22.03B
Dexcom
DXCM
Mkt Cap22.71B
Abbott Laboratories
ABT
Mkt Cap214.96B
About
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Show more...
CEO
Dr. Michael E. Castagna Pharm.D.
Employees
403
Country
US
ISIN
US56400P7069
Listings
0 Comments
Share your thoughts
FAQ
What is Mannkind stock price today?▼
The current price of MNKD is $6.01 USD — it has increased by +3.98% in the past 24 hours. Watch Mannkind stock price performance more closely on the chart.
What is Mannkind stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mannkind stocks are traded under the ticker MNKD.
Is Mannkind stock price growing?▼
MNKD stock has risen by +7.97% compared to the previous week, the month change is a +7.59% rise, over the last year Mannkind has showed a +4.06% increase.
What is Mannkind market cap?▼
Today Mannkind has the market capitalization of 1.85B
When is the next Mannkind earnings date?▼
Mannkind is going to release the next earnings report on March 03, 2026.
What were Mannkind earnings last quarter?▼
MNKD earnings for the last quarter are 0.03 USD per share, whereas the estimation was 0.02 USD resulting in a +60% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mannkind revenue for the last year?▼
Mannkind revenue for the last year amounts to 571.01M USD.
What is Mannkind net income for the last year?▼
MNKD net income for the last year is 55.18M USD.
How many employees does Mannkind have?▼
As of February 02, 2026, the company has 403 employees.
In which sector is Mannkind located?▼
Mannkind operates in the Health Care sector.
When did Mannkind complete a stock split?▼
The last stock split for Mannkind was on March 03, 2017 with a ratio of 1:5.
Where is Mannkind headquartered?▼
Mannkind is headquartered in Danbury, US.